Compare Heron Therapeutics Inc (HRTX) vs JetBlue Airways Corporation (JBLU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs JetBlue Airways Corporation — how do they compare? Heron Therapeutics Inc trades at $0.37 (market cap $74.04M), while JetBlue Airways Corporation trades at $3.91 (market cap $1.50B). The key difference: JetBlue Airways Corporation is far larger — about 20.3× Heron Therapeutics Inc's market cap, and JetBlue Airways Corporation is more actively traded (22,018,927 versus 3,668,095). Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and JetBlue Airways Corporation for 44 Days on average.
| HRTX | JBLU | |
|---|---|---|
Market Cap | $74.04M | $1.50B |
Volume | 3,668,095 | 22,018,927 |
Sector | Health | Industrials |
52-Week High | $1.49 | $6.46 |
52-Week Low | $0.27 | $3.92 |
Typical Hold Time | 35 Days | 44 Days |
Enterprise Value | $180.78M | $8.86B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.39, up 17.58% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings performance discussions.
The outlook is mixed: strong analyst support and technical momentum suggest potential upside, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on revenue growth translating to profitability, while key risks include execution challenges and competitive pressures in the biotechnology sector.
JetBlue (JBLU) trades at $3.92, down 2.73% on the day, reflecting ongoing challenges. The stock shows a bearish technical trend with key indicators mixed, while fundamentals reveal persistent losses with a negative net income margin of -9.32% and elevated debt levels. Recent news includes route expansion to Colombia but also capacity cuts due to fuel costs, highlighting operational pressures amid a difficult industry environment.
The outlook remains cautious with high debt and consistent earnings misses posing significant risks. However, the consensus price target of $5.89 suggests potential upside if operational improvements materialize. Investors face headwinds from fuel price volatility and competitive pressures, requiring careful monitoring of cost management and travel demand recovery for any sustained rebound.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About JetBlue Airways Corporation
JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It carries over millions of customers with an average of more than 1,000 daily flights and served approximately 99 destinations in the United States, the Caribbean, and Latin America. The company currently operates Airbus A321, Airbus A320, and Embraer E190 aircraft types.
Read more on JBLU →
